IL17A and diabetes mellitus: Interventions with anti-IL-17 antibodies or IL-2 - a negative regulator of Th17 responses—prevented insulitis (18) and remitted diabetes (19), whereas IL-23 administration, which enhances IL-17 and TNF-α production, exacerbated β-cell damage (20).